Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
0(0%)
Results Posted
120%(12 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_3
2
15%
Ph phase_2
2
15%
Ph phase_1
8
62%

Phase Distribution

8

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
8(66.7%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(10)
Terminated(2)
Other(1)

Detailed Status

Completed10
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (66.7%)
Phase 22 (16.7%)
Phase 32 (16.7%)

Trials by Status

completed1077%
terminated215%
unknown18%

Recent Activity

0 active trials
Showing 5 of 13
terminatedphase_3

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

NCT05047523
completedphase_1

Copper Balance in Healthy Participants Administered ALXN1840

NCT04594252
completedphase_2

Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

NCT04573309
terminatedphase_3

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

NCT03403205
completedphase_1

Bioavailability Study of 2 Oral Formulations of ALXN1840

NCT04610580
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05047523Phase 3

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Terminated
NCT04594252Phase 1

Copper Balance in Healthy Participants Administered ALXN1840

Completed
NCT04573309Phase 2

Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

Completed
NCT03403205Phase 3

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Terminated
NCT04610580Phase 1

Bioavailability Study of 2 Oral Formulations of ALXN1840

Completed
NCT05641311Phase 1

Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants

Completed
NCT04526210Phase 1

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Completed
NCT04526197Phase 1

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

Completed
NCT04560816Phase 1

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Completed
NCT05303324Phase 1

Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults

Completed
NCT05319899Phase 1

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

Completed
NCT05686564

Early Access Program for ALXN1840 in Patients With Wilson Disease

Unknown
NCT02273596Phase 2

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13